6 documents found, page 1 of 1
Changes in the color and sensitivity of the tongue in adult women after COVID-1...
Fontes, Luciana; Correia, Maria da Conceição; Marques, Kátia; Fontes, Pedro; Silva, Nayara; Gomes, Marília; Fernandes, Rita; Cunha, DanieleObjectives: to describe the changes in color and sensitivity of the tongue in adult women, in the period after the treatment of COVID-19 and explain the dental conduct for treatment. Case report: there was a request for dental evaluation by a public and reference University Hospital in the city of Recife, northeast of Brazil. The patient in question was a 33 years-old white female. There was a history of diagno...
Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With...
Carvalho, Susana; Gomes, Marília; Marques, Herlander; Pereira, Catarina; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos; Sottomayor, CarlosIntroduction: To perform a cost-effectiveness analysis of follicular lymphoma maintenance treatment after first-line induction with rituximab compared to observation in Portugal.Methods: A Markov follicular lymphoma model was developed with four health states: progression free survival on first and second lines, progression and death. The transition probabilities between health states were obtained from the PRI...
Eritropoietina Sérica como Marcador Prognóstico em Síndrome Mielodisplásica
Cortesão, Emília; Tenreiro, Rita; Ramos, Sofia; Pereira, Marta I.; César, Paula; Carda, José P.; Gomes, Marília; Rito, Luís Carlos; Magalhães, EmíliaIntrodução: A síndrome mielodisplásica é uma doença heterogénea caracterizada por displasia, medula hipercelular, citopenias e risco de evolução para leucemia aguda. Outros factores de prognóstico, nomeadamente, fibrose medular, elevação da enzima desidrogenase do lactato e β2-microglobulina têm sido descritos, contudo, a decisão terapêutica baseia-se no score do International Prognostic Scoring System. Materia...
Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes
Cortesão, Emília; Tenreiro, Rita; Ramos, Sofia; Pereira, Marta; César, Paula; Carda, José P.; Gomes, Marília; Rito, Luís; Magalhães, EmíliaIntroduction: This myelodysplastic syndromes are a heterogeneous entity characterized by dysplasia, hypercellular bone marrow, cytopenias and risk of transformation to acute leukaemia. Prognostic factors, such as bone marrow fibrosis, lactate dehydrogenase and β2-microglobulin elevation have been described, but treatment is mainly based in the International Prognostic Scoring System.Material and Methods: Our ai...
The rs5743836 polymorphism in TLR9 confers a population-based increased risk of...
Carvalho, Agostinho; Cunha, Cristina; Almeida, A. J.; Osório, Nuno S.; Saraiva, Margarida; Coelho, Maria Teixeira; Pedreiro, Susana; Torrado, EgídioNon-Hodgkin lymphoma (NHL) has been associated with immunological defects, chronic inflammatory and autoimmune conditions. Given the link between immune dysfunction and NHL, genetic variants in toll-like receptors (TLRs) have been regarded as potential predictive factors of susceptibility to NHL. Adequate anti-tumoral responses are known to depend on TLR9 function, such that the use of its synthetic ligand is b...
Economic analysis of rituximab in combination with cyclophosphamide, vincristin...
Braga, Paula; Carvalho, Susana; Gomes, Marília; Guerra, Lurdes; Lúcio, Paulo; Marques, Herlander; Negreiro, Filipa; Pereira, Catarina; Silva, CatarinaEvaluate costs and benefits of rituximab in combination with cyclophosphamide/vincristine/prednisolone chemotherapy regimen (R-CVP), in previously untreated patients with indolent non-Hodgkin lymphoma (NHL), compared to CVP alone from a Portuguese National Health System (NHS) perspective.Cost-effectiveness (Life Years Gained--LYG) and cost-utility analysis (Quality Adjusted Life Years--QALYs) were performed for...